GLP-1 medications like Wegovy and Zepbound have rapidly reshaped metabolic care, expanding from Type 2 diabetes treatment to widely used weight management tools when combined with diet and exercise. This surge in use is driving complex, high-cost decisions for employer-sponsored health plans.
With employee interest rising and clinical evidence growing, more organizations are evaluating whether GLP-1 coverage is sustainable. In 2025, KFF reported that 19% of employers with 200+ workers and 43% with 5,000+ workers covered GLP-1s for weight loss, and employers are expected to revisit coverage and cost-containment strategies each year as demand remains high.
GLP-1 medications remain a major driver of rising health care costs in 2026 as more employers add coverage for weight loss. RAND reports that 12% of Americans have used GLP-1s for weight loss and another 14% are interested, with prescriptions more than tripling since 2020. KFF estimates that over 57 million privately insured adults meet clinical criteria for these drugs, yet fewer than 1 in 5 large employers cover them for weight loss.
This growing gap between employee demand and plan coverage is pushing employers to decide if GLP-1s are essential to a competitive benefits package and how to manage the significant financial exposure if they opt in.
GLP‑1 medications carry high, persistent costs and are designed for long‑term use, making them some of the most expensive chronic drugs on a plan. As utilization grows, they now account for about 10.5% of annual pharmacy claims, up from 6.9% in 2023. Modeling from the Employee Benefit Research Institute shows that broader GLP‑1 coverage can increase employer health premiums by 6% to nearly 14% a year, even with cost‑sharing in place. At the same time, a 2026 Aon analysis found that sustained GLP‑1 use for employees with Type 2 diabetes was associated with 6% lower medical cost growth after 30 months, highlighting both the budget impact and the potential long‑term savings.
Employers that cover GLP‑1s are seeing gains in employee satisfaction and retention, as obesity care becomes a higher priority for working‑age adults. In fact, the 2026 NFP U.S. Benefits Trend Report found that 29% of employees would switch employers to access GLP‑1 benefits. However, nearly half of users stop treatment within 12 months, especially those using GLP‑1s for obesity alone. Without strong lifestyle and behavioral support alongside coverage, it can be difficult for employers to realize the full health and productivity benefits.
Early evidence shows GLP‑1s can lower certain medical costs, especially hospitalizations tied to diabetes and obesity‑related conditions. One AssuredPartners case study found GLP‑1 users saved about $560 per person per year in medical costs but against an average annual drug cost of $6,540, the near‑term ROI is negative for most employers. At the same time, obesity already costs the U.S. health system an estimated $173 billion annually, with $1,800–$3,000 in additional medical costs per adult each year.
While GLP‑1s are expensive, they can deliver meaningful weight loss, better metabolic control, and reduced cardiovascular risk, which may translate into fewer hospitalizations and long‑term workforce health gains.
One of the toughest parts of the GLP‑1 equation is adherence. When employees stay on therapy, outcomes improve but so do claims costs, as high monthly drug spend compounds over time. Models show premiums rise several percentage points more under perfect adherence than under real‑world use, because costs outpace savings in the short term.
And with average employee tenure around four years, many employers may not keep workers on their plan long enough to recoup those costs through lower medical utilization. As a result, GLP‑1 coverage can remain financially challenging even as its clinical value becomes more evident and the “right” strategy can vary widely by employer.
In response, many employers are moving away from open‑ended GLP‑1 coverage and shifting to more targeted, cost‑controlled strategies, such as:
Using pre-tax HRA dollars can help offset GLP‑1 costs. Employees pay upfront, submit eligible claims, and receive tax‑advantaged reimbursement from the HRA.
GLP‑1 medications can be a powerful way to address Type 2 diabetes and obesity and support a healthier, more productive workforce but they come with a substantial price tag. For most employers, broad coverage increases overall health spending and puts upward pressure on premiums. The most sustainable path is a balanced strategy: targeted eligibility, strong utilization management, integration with lifestyle programs, and thoughtful plan design.
As the GLP‑1 market matures and lower‑cost options emerge, employers that take a measured, data‑driven approach now will be better positioned to adjust their benefits strategy over time. Download the bulletin for more details.